drugset / Trial / NCT00866528
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Timeline
- Start
- 2009-07-09
- Primary completion
- 2012-10-25
- Completion
- 2012-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |